Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Justin Ferdinandus; Francesco Barbato; Michal Chodyla; Wolfgang P. Fendler; Lukas Kessler; Kelsey L. Pomykala; Martin Metzenmacher; Frederik Krefting; Thomas Hager; Lale Umutlu; Ken Herrmann; Daniel C. Christoph

doi:10.2967/jnumed.120.245803

Research ArticleOncology

Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Justin Ferdinandus, Francesco Barbato, Michal Chodyla, Wolfgang P. Fendler, Lukas Kessler, Kelsey L. Pomykala, Martin Metzenmacher, Frederik Krefting, Thomas Hager, Lale Umutlu, Ken Herrmann and Daniel C. Christoph

Journal of Nuclear Medicine February 2021, 62 (2) 191-194; DOI: https://doi.org/10.2967/jnumed.120.245803

Justin Ferdinandus

1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francesco Barbato

1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michal Chodyla

2Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang P. Fendler

1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lukas Kessler

1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kelsey L. Pomykala

1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany

3Department of Radiology, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Metzenmacher

4Department of Medical Oncology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frederik Krefting

5Department of Dermatology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Hager

6Institute of Pathology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lale Umutlu

3Department of Radiology, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ken Herrmann

1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daniel C. Christoph

4Department of Medical Oncology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue 2

February 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Journal of Nuclear Medicine Feb 2021, 62 (2) 191-194; DOI: 10.2967/jnumed.120.245803

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Journal of Nuclear Medicine Feb 2021, 62 (2) 191-194; DOI: 10.2967/jnumed.120.245803

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Oncology

Comparative PSMA expression at early (1hour) vs late (2hour) in primary and secondary sites of involvement in prostate cancer.
Imaging spectrum of peritoneal carcinomatosis associated with various etiologies on 18F-FDG PET/CT
Diagnostic Role of 18F-FDG PET/CT in Urothelial carcinoma and its impact on management, and prognosis : A case based approach

Show more Oncology

Clinical

Addition of ¹³¹I-MIBG to PRRT (⁹⁰Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
SUVs Are Adequate Measures of Lesional ¹⁸F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?

Show more Clinical

Keywords

mesothelioma
checkpoint inhibitor
pembrolizumab
PET/CT

Main menu

User menu

Search

Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oncology

Clinical

Similar Articles

Keywords